Osaka – Osaka Mayor Ichiro Matsui has said that a clinical trial of a vaccine for the novel coronavirus will begin at a hospital in the city on June 30.
The vaccine was developed by AnGes Inc., a biopharmaceutical startup related to Osaka University. The clinical trial will take place at Osaka City University Hospital, Matsui said Tuesday.
According to sources, the firm will carry out the trial with the participation of 30 applicants, including medical professionals, after completing animal testing on Monday.
Matsui stressed the importance of developing a vaccine in Japan. He added that he was told by Osaka University professor Ryuichi Morishita, who founded AnGes, that the vaccine “will become available to the general public between spring and autumn next year.”
In April this year, the city, which is the capital of Osaka Prefecture, and the prefectural government agreed with Osaka University and Osaka City University to cooperate in the development of a vaccine for the virus.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.